Collectively, antineoplastic chemotherapy, myeloablative and conditioning regimens for HSCT, alkylating chemo agents, regimens containing bleomycin, busulfan, cyclophosphamide, gemcitabine, taxanes, G-CSF, FOLFOX/FOLFIRI produce lung injury including pulmonary edema, ARDS, diffuse alveolar hemorrhage and noninfectious lung injury. See under each specific drug or agent including radiation therapy and/or TBI. In a sizable fraction of patients, identification of the causal agent is difficult. A likelihood analysis is performed relating incidence, clinical, imaging and pathologic pattern of injury and the specific drug. Toxicity in lung cancer see PMID 21283982. The risk of developing pulmonary toxicity with chemotherapy may be increased in patients with preexisting ILD or IPF (PMID 19420811, 23171837, 25316105)

Last update : 17/04/2019
I - Interstitial/parenchymal lung disease
II - Pulmonary edema - Acute lung injury - ARDS
III - Pulmonary/alveolar./airway hemorrhage/bleeding
IV - Airway involvement
V - Pleural and/or pericardial involvement
VI - Pulmonary vasculopathies
VII - Mediastinal involvement
VIII - Central-large-upper airway (incl. pharyngeal-nasal) involvement
IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
X - Systemic/Distant conditions, syndromes and reactions
XI - Miscellaneous
XII - Cardiovascular involvement / toxicity
XIII - Neoplastic conditions
XV - Pathology
XVI - Imaging
XVII - Infections & related conditions
XIX - Cytological, biochemical features of/in BAL, pleural fluid or FNA